全球类风湿关节炎药物市场 – 行业趋势及 2029 年预测

类风湿关节炎药物市场分析及规模

类风湿性关节炎药物会影响日常活动的表现，包括家务和工作，还会导致死亡。经常吸烟的人患类风湿性关节炎药物的风险更高。在全球范围内，几家领先的市场参与者通过收购面临大量产品召回的公司来维持其市场地位。此外，有利的报销政策和不断增长的医疗保健支出推动了市场扩张。

Data Bridge Market Research 分析了 2022-2029 年预测期内全球类风湿性关节炎药物市场的增长率。在上述预测期内，全球类风湿性关节炎药物市场的预期复合年增长率约为 21.45%。2021 年市场价值为 600.2 亿美元，到 2029 年将增长至 2841.0 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

类风湿关节炎药物市场范围和细分

Market Definition

Rheumatoid arthritis is a chronic inflammatory, an autoimmune disorder that can affect joints and several other body parts such as skin, eyes, lungs, and blood vessels. This disease affects the lining of joints, leading to a painful inflammation that can eventually result in bone erosion and joint deformity. Regarding its treatment, physiotherapy and medication involving corticosteroids, NSAIDs and many others can help slow down the disease progression. 

Global Rheumatoid Arthritis Drugs Market Dynamics

Drivers

• High Prevalence of Arthritis

It has been witnessed that more than 350 million people have arthritis globally. In the U.S., 1 in 4 adults was recorded with arthritis in 2020. It is projected to be 78 million by the year 2040. In addition, in the U.S., around 52.2 million people were affected with rheumatoid arthritis in 2013. This boosts market growth.

• Growing Development in Biologics

The increased availability, low price, and favorable results of biologics are the factors boosting the market's growth. Their demand is higher in developing nations, whereas in industrialized nations, the demand is increasing due to the introduction of newer, more effective products. For instance, Glenmark Pharmaceuticals launched a biosimilar for Humira in India in January 2018. New biosimilars are anticipated to cause a huge shift in prescription patterns in upcoming years. Thus, growing advancements in biologics is creating huge opportunities for the growth of global rheumatoid arthritis drugs market.

Opportunities

• Advance Clinical Research Associated with Biologics

Different combinations of biologics for the treatment of RA are anticipated to achieve complete control of joint inflammation and destruction. Although the first trial of combination therapy with anakinra and abatacept increased the chances of infection, TNF inhibitors and interleukin-17 inhibitors such as secukinumab are considered more promising therapy. Thus, all these researchers are creating many opportunities for market growth.

• Increased Technological Advancements

Novel technologies to improve the therapeutic potential of bi-specific antibodies and novel targets, such as JAK enzymes, have created several new opportunities for rheumatoid arthritis treatment. Many of the key market players have combination DMARD therapies in their pipelines. Many of these programs involve investigation of new or existing biological therapies with adalimumab- the highest-selling antirheumatic drug worldwide. Additionally, the new era of bi-specific antibodies is anticipated to push market growth during the forecast period

Restraints/Challenges

• Lack of resources in Under-Developed Nations

Under-developed countries do not have many resources for developing rheumatoid arthritis drugs. Thus, the lack of resources in many of these countries poses a major challenge to expanding the rheumatoid arthritis drugs market worldwide.  

• High Cost

The high cost of pharmaceuticals is very expensive, making it difficult for an average person to afford the treatment. Many therapy types and drugs are quite expensive, and thus, they pose a major hindrance to the market.

This global rheumatoid arthritis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global rheumatoid arthritis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In November 2019, Pfizer announced the FDA approval of its biosimilar, abrilada, for treating multiple inflammatory conditions.
• In 2020, Mylan announced that the FDA approved Hulio. It is a TNF inhibitor that is intended to treat patients with rheumatoid arthritis drugs, psoriatic arthritis, juvenile idiopathic arthritis, adult Crohn's disease, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis.

Global Rheumatoid Arthritis Drugs Market Scope

The global rheumatoid arthritis drugs market is segmented on the basis of drugs, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Ibuprofen
• Naproxen
• Diclofenac
• Corticosteroid
• Aristocort
• Bubbli-Pred
• Disease-modifying antirheumatic drugs (DMARDs)
• Methotrexate
• Sulfasalazine
• Janus Kinase (JAK) Inhibitors
• Cibinqo
• Jyseleca
• Biologic Agents
• Others

Route of Administration

• Oral
• Parenteral
• Topical
• Others

最终用户

• 医院
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 零售药店
• 其他的

类风湿关节炎药物市场区域分析/见解

对全球类风湿性关节炎药物市场进行了分析，并按上述药物、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

全球类风湿性关节炎药物市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于类风湿性关节炎患病率不断上升以及早期诊断技术的进步，北美占据了市场主导地位。

由于关节置换手术的增加、通过广告和媒体对关节疾病的认识的提高以及该地区医疗保健基础设施的快速改善，预计亚太地区将占据最大的市场份额。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球类风湿关节炎药物市场份额分析

全球类风湿性关节炎药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球类风湿性关节炎药物市场的关注有关

全球类风湿关节炎药物市场的主要参与者包括：

• 辉瑞公司（美国）
• Abbvie Inc.（美国）
• 诺华公司（瑞士）
• 安进公司 (美国)
• 勃林格殷格翰国际有限公司（德国）

• 默克公司（美国）
• 太阳制药工业有限公司 (印度)
• Teva Pharmaceuticals Industries Ltd.（以色列）
• 阿斯利康（英国）
• Ampio Pharmaceuticals Inc.（美国）
• 礼来（美国）
• 费森尤斯卡比公司（德国）
• 拜耳公司（德国）
• Casper Pharma（美国）
• Dr. Reddy's Laboratories Ltd.（印度）
• 诺布鲁克（英国）

研究方法：全球类风湿关节炎药物市场  

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（Factbook）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

SKU-55624